Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3383MR)

This product GTTS-WQ3383MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam CD52 gene. The antibody can be applied in Canine T-cell lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001003240.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403918
UniProt ID Q28896
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3383MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13591MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ10604MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ10650MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ7379MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ7723MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ986MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ8641MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ14877MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW